Regulatory T cells (T reg cells) suppress autoreactive immune responses and limit the efficacy of tumor vaccines; however, it remains a challenge to selectively eliminate or inhibit T reg cells. In this study, the zinc-finger A20, a negative regulator of the Toll-like receptor and tumor necrosis factor receptor signaling pathways, was found to play a crucial part in controlling the maturation, cytokine production and immunostimulatory potency of dendritic cells (DCs). A20-silenced DCs showed spontaneous and enhanced expression of costimulatory molecules and proinflammatory cytokines and had different effects on T cell subsets: they inhibited T reg cells and hyperactivated tumor-infiltrating cytotoxic T lymphocytes and T helper cells that produced interleukin-6 and tumor necrosis factor-a and were refractory to T reg cell-mediated suppression. Hence, this study identifies A20 as an antigen presentation attenuator in control of antitumor immune responses during both the priming and the effector phases and provides a strategy to overcome T reg cell-mediated suppression in an antigen-specific manner, reducing the need to directly target T reg cells.
Tumor vaccines, including DC vaccines 1 , can activate potent cytotoxic T lymphocyte (CTL) responses against self tumor-associated antigens (TAA); however, they have been largely ineffective in causing tumor regression in the clinic [2] [3] [4] . Moreover, autoimmune pathologies are rarely observed in immunized patients, indicating that peripheral tolerance is still maintained at the host level 5 . CD4 + CD25 + Foxp3 + T reg cells have an essential role in suppressing autoimmune responses, including those against TAA 6, 7 . T reg cells were found to migrate to and accumulate inside tumors, where they inhibit the effector function of infiltrating immune cells [8] [9] [10] [11] . Therefore, overcoming T reg cellmediated immune suppression is required for the induction of effective antitumor immunity.
A direct means to overcome T reg cell-mediated immune suppression is to inhibit or deplete CD4 + CD25 + Foxp3 + T reg cells by using antibodies to CD25 or interleukin-2 (IL-2)-toxin fusion proteins [12] [13] [14] . CD25 molecules, however, are highly expressed on activated effector T cells, and so far no unique surface marker expressed on T reg cells has been identified 6, 7 . Alternatively, antagonist antibodies to cytotoxic T lymphocyte antigen-4 or agonist antibodies to glucocorticoidinduced tumor necrosis factor receptor (GITR) can overcome T reg cell-mediated suppression by overactivating CTLs 15, 16 . However, the nonspecific overactivation of self-reactive T cells, unsatisfactory clinical efficacy and pathological autoimmune toxicity that has been observed in clinical trials of these antibodies [17] [18] [19] may restrict the clinical usefulness of these strategies. Thus, it is desirable to develop an approach that could override T reg cell-mediated suppression in an antigen-specific manner without compromising effector T cells.
The zinc-finger protein A20 is a ubiquitin-modifying enzyme that negatively regulates the tumor necrosis factor receptor (TNFR) and Toll-like receptor (TLR) signaling pathways [20] [21] [22] [23] . A20 regulates the degradation of several key molecules, such as receptor-interacting protein and TNFR-associated factors 2 and 6, which are crucial in nuclear factor-kB activation, via its dual functions of ubiquitination and deubiquitination [20] [21] [22] [23] [24] . A20-deficient mice show severe inflammation in multiple organs, are hypersensitive to endotoxin shock and die as newborns. A20-deficient macrophages produce elevated levels of pro-inflammatory cytokines after stimulation with TLR ligands [20] [21] [22] , indicating an essential role for A20 in the maintenance of selftolerance. In this study, we reveal a crucial regulatory role of A20 in antigen presentation by DCs. We demonstrate that A20 silencing endows DCs with unique abilities to hyperactivate CTLs and T helper cells and inhibit T reg cells, providing a strategy to overcome T reg cell-mediated suppression of antitumor immunity in an antigen-specific manner.
RESULTS

A20 negatively regulates DC maturation and cytokine production
To investigate the possible role of A20 in regulating antigen presentation, we first examined the expression of A20 mRNA in myeloid DCs derived from mouse bone marrow. Quantitative RT-PCR (qRT-PCR) assays showed that the levels of A20 mRNA in DCs were increased by stimulation with a TLR agonist ( Supplementary Fig. 1 online) . We generated a recombinant lentiviral vector expressing a short hairpin interfering RNA (siRNA) that effectively silences mouse A20 mRNA in DCs (LV-siA20; Fig. 1a) . To examine the role of A20 in regulating DC maturation, we used flow cytometric assays to analyze surface expression of various molecules related to antigen presentation. LV-siA20-transduced DCs (siA20-DCs) showed significantly higher levels of CD80, CD86, CD40, and major histocompatibility complex (MHC) class II than LV-siGFP-infected (control) BMDCs (Fig. 1b) . The expression of GITR ligand (GITR-L) and OX40L was also significantly enhanced on siA20-treated DCs (Fig. 1b) . Notably, we found that siA20-DCs spontaneously produced high amounts of proinflammatory cytokines such as IL-6, TNF-a and IL-12p40 (Fig. 1c) . In contrast, siGFP-DCs spontaneously produced undetectable or very low levels of these cytokines. Furthermore, siA20-DCs produced higher amounts of these proinflammatory cytokines in response to stimulation by TLR agonists than did siGFP-DCs (Fig. 1c) . LV-siA20-transduced DCs and LV-siGFP-transduced DCs had comparable viability in cell culture in the presence or absence of the TLR agonist ( Supplementary Fig. 2 online) , despite the reported anti-apoptotic role of A20 in other types of cells 20 . Collectively, these results indicate that A20 negatively regulates the maturation and cytokine production of DCs and that DCs with A20 knockdown are spontaneously activated and hyperactivated in response to TLR agonists.
A20-silenced DCs prime enhanced T cell responses in vivo
We tested whether the immunostimulatory potency of DCs is regulated by A20. Mice were immunized with ovalbumin (OVA)-pulsed, LV-siA20-transduced or LV-siGFP-transduced DCs matured ex vivo with lipopolysaccharide (LPS), and the functional status of T cells was then evaluated using interferon-g (IFN-g) enzymelinked immunosorbent spot (ELISPOT) assays and intracellular cytokine staining. Mice given siA20-DCs had higher numbers of IFN-g + CD4 + and IFN-g + CD8 + T cells compared to mice given siGFP-DCs (Fig. 2a-f) . Moreover, antigen-specific T cell responses were also enhanced in mice immunized with OVA-pulsed DCs transfected with siA20 oligonucleotide duplexes (Supplementary Fig. 3 online) . We also observed that in vivo TLR ligand (polyI:C) stimulation of mice that had been immunized with DCs 1 d earlier more effectively boosted OVA-specific CTL responses than did siA20-DCs (Figs. 2a-c) .
We then tested whether siA20-DCs can enhance the immune response against self tumor-associated antigens, such as tyrosinaserelated protein-2 (TRP2) 25, 26 . siA20-DCs induced more potent antigen-specific CD8 + T cell responses against mouse TRP2, and in vivo polyI:C stimulation more effectively boosted siA20-DC immunization (Fig. 2d,f) . In agreement with these results, CTL responses against another self antigen, survivin 27, 28 , were also significantly enhanced in the siA20-DC-treated mice (Fig. 2e) . These data show a role for A20 as an antigen presentation attenuator in control of the immunostimulatory potency of DCs and the magnitude of T cell responses.
A20-silenced DCs overcome T reg Cell suppression in vivo
We investigated whether A20-silenced DCs may induce potent antitumor immunity with the ability to control the growth of pre-established tumors. Immunization with OVA-pulsed siA20-DCs inhibited the growth of pre-established B16-OVA tumors, in contrast to the modest reduction in tumor growth in mice given OVA-pulsed siGFP-DCs ( Supplementary Fig. 4 online) . Moreover, immunization with OVA-loaded DCs transfected with siA20 oligonucleotide duplexes also induced enhanced antitumor activity in an EG.7 tumor model ( Supplementary Fig. 5 online) .
The enhanced ability of A20-silenced DCs to control tumor growth in wild-type mice prompted us to investigate the potency of the antitumor response induced by siA20-DC immunization compared with that induced in mice depleted of CD25 + T reg cells with a monoclonal antibody (clone PC61) to CD25 or with combined siGFP-DC immunization and T reg cell depletion. C57BL/6 mice were inoculated with B16-OVA cells and then treated with OVA-pulsed siA20-DCs or siGFP-DCs 3 and 10 d later. Antibodies to CD25 were administered intraperitoneally (i.p.) into groups of mice on days 1 and 5 before DC immunization, owing to the high expression of CD25 on activated CD4 + and CD8 + T cells and to impaired antitumor efficacy by antibody-mediated CD25 depletion after tumor vaccination 13, 29 . A single administration of antibodies to CD25 was found to deplete more than 90% of CD4 + CD25 + T cells for a week, which is consistent with a previous report 30 . siGFP-DCs or CD25-specific antibody treatment alone had only moderate or marginal inhibitory effects on the growth of B16-OVA tumors (Fig. 3) . In contrast, OVA-pulsed siA20-DC immunization alone effectively inhibited the growth of pre-established B16-OVA tumors (Fig. 3a) . Notably, siA20-DC immunization alone was as effective as the combined siGFP-DC and CD25-specific antibody treatment in controlling the growth of preestablished B16-OVA tumors (Fig. 3a) . We also examined systemic T cell responses in B16-OVA tumor-bearing mice that were immunized with different regimens, as described above. The frequencies of OVA-specific CD8 + T cells in spleens of the siA20-DC-treated mice were significantly higher than those in siGFP-DC-treated and CD25-specific antibody-treated mice (Fig. 3c,d ).
We further compared the potency of these immunization regimens in a different tumor model, the mouse A20 B cell lymphoma, which naturally expresses survivin 27 . We observed that CD25-specific antibody treatment or mouse survivin peptide-pulsed siGFP-DC immunization alone had no apparent inhibitory effect on A20 tumor growth (Fig. 3b) . The inability of CD25-specific antibodymediated depletion of T reg cells alone to control pre-established tumors has been previously reported 13 . In contrast to those results, survivin-pulsed siA20-DCs, as well as the combined CD25-specific antibody and survivin-pulsed siGFP-DC treatment, effectively inhibited the growth of pre-established A20 tumors (Fig. 3b) . Taken together, these results indicate that A20-silenced, hyperactivated DCs induce an effective antitumor response capable of overriding T reg cell-mediated immune suppression in wild-type mice.
Superior immunostimulatory potency and antitumor activity
In our previous study, we showed that inhibition of the suppressor of cytokine signaling-1 (SOCS1), a key negative regulator of JAK/STAT signaling, enhanced the immunostimulatory potency of DCs 31, 32 . To investigate whether siA20-DCs are superior to siSOCS1(siS1)-DCs (DCs transduced with LV-SiSOCS1) in mediating immunostimulation, we immunized groups of mice with the same number of different transduced DCs pulsed with OVA protein. siA20-DCs more efficiently induced antigen-specific CD8 + CTLs and CD4 + T helper cell responses than did siS1-DCs (Fig. 4a,b) . Because A20 and SOCS1 negatively regulate different signal transduction pathways, we investigated whether silencing of both A20 and SOCS1 has a synergistic effect on the immunostimulatory potency of DCs. We found that DCs cotransfected with LV-siA20 and LV-siS1 (siAS) were slightly more potent than siA20-DCs and siS1-DCs in inducing T cell responses (Fig. 4a,b) . Furthermore, siA20-DC immunization more effectively inhibited the growth of pre-established tumors than did siS1-DC immunization (Fig. 4c) .
SiA20-DCs inhibit T reg cells and hyperactivate effectors
To investigate the superior immunostimulatory potency of siA20-DCs, we first examined the effects of siA20-DCs on CD8 + CTLs and CD4 + CD25 -T helper cells in vitro. siA20-DCs, siS1-DCs, siAS-DCs and siGFP-DCs loaded with OVA-I peptide SIINFEKL and matured with LPS were cocultured with CD8 + OT-I cells isolated from transgenic mice expressing a T cell receptor (TCR) specific for OVA MHC class I peptide in the presence or absence of T reg cells or B16 tumor lysate supernatant that contains various tumor-derived suppressive factors 33 . siA20-DCs more potently stimulated the proliferation of OT-I cells than siS1-DCs (Fig. 5a) . Of note, siA20-DCs that were pretreated with T reg cells or B16 tumor lysate were still able to effectively stimulate the proliferation of OT-I cells (Fig. 5a) . In contrast, the ability of siS1-DCs to stimulate the proliferation of OT-I cells was more severely inhibited by T reg or B16 tumor lysate (Fig. 5a ). In agreement with these results, siA20-DCs were also more potent in stimulating the proliferation of CD4 + CD25 -OT-II cells isolated from transgenic mice expressing OVA MHC class II peptide-specific TCR (data not shown). These results show the superior immunostimulatory potency of A20-silenced DCs to activate CTLs and T helper cells even in immune suppressive environments. We also examined the effect of A20-silenced DCs on the suppressive activity and proliferation of T reg cells. LPS-activated DCs were all shown to have an inhibitory effect on the suppressive activity of CD4 + CD25 + T reg cells (Fig. 5b) , which is in agreement with previous reports [34] [35] [36] [37] . However, only siA20-DCs without LPS maturation inhibited the suppressive activity of T reg cells (Fig. 5b) . To investigate the mechanisms of this unique suppressive ability of siA20-DCs, we compared the amounts of representative proinflammatory cytokines secreted by siA20-DCs and siS1-DCs. siS1-DCs without stimulation spontaneously produced undetectable or low levels of proinflammatory cytokines, which is in contrast to the high levels of IL-6, TNF-a and IL-12p40 spontaneously produced by unstimulated siA20-DCs (Fig. 1c) . The amounts of the proinflammatory cytokines produced by siS1-DCs in response to LPS were also lower than those produced by siA20-DCs, although siS1-DCs produced higher amounts of these cytokines than did siGFP-DCs (Fig. 1c) . Moreover, there were no apparent increases in the levels of various surface costimulatory molecules on siS1-DCs, compared to those on siGFP-DCs (Fig. 1b) . In contrast, the surface levels of these costimulatory molecules on siA20-DCs were significantly enhanced (Fig. 1b) . Given the increased production of IL-6 and TNF-a by siA20-DCs and the reported ability of these proinflammatory cytokines to inhibit T reg cells 16, 34, [38] [39] [40] [41] [42] , we used antibodies against IL-6 and TNF-a to examine the effect of these soluble factors on T reg cells. The addition of both antibody to TNF-a and antibody to IL-6 significantly reversed the inhibitory effect of siA20-DCs on T reg cells' suppressive activity, whereas either antibody to TNF-a or antibody to IL-6 alone moderately reversed the inhibitory effect of siA20-DCs on T reg cells ( Fig. 5c) . Moreover, we compared antitumor responses induced by wild-type DCs and DCs derived from TNF-a-knockout mice. When we used TNF-a-knockout siA20-DCs loaded with OVA to immunize wild-type, the DCs were no longer able to effectively inhibit the growth of B16-OVA tumors ( Supplementary Fig. 6 online) . In addition, siA20-DCs derived from TNFR-knockout mice (TNFR-KO siA20-DC) also showed a substantially reduced ability to induce tumor regression ( Supplementary Fig. 7 online) , suggesting the importance of a TNFR signaling network initiated by TNF-a produced by antigen-presenting siA20-DCs for inducing antitumor immunity. We further investigated the effect of siA20-DCs on T reg cell proliferation. In contrast to their enhanced immunostimulatory potency to CTLs and T helper cells, siA20-DCs showed a reduced ability to stimulate CD4 + CD25 + T reg cell proliferation, as compared with siGFP-DCs (Fig. 5d) . However, siS1-DCs did not have this reduced ability. BMDCs without LPS maturation were unable to stimulate CD4 + CD25 + T reg cells in the presence of antibodies to CD3, in agreement with a previous report 35 . To confirm this in vitro observation, we examined the ability of OVA-pulsed, LPS-matured BMDCs to stimulate OT-II CD4 + CD25 + T reg cell proliferation in vivo. siA20-DCs, but not siS1-DCs, had a reduced ability to stimulate the proliferation of adoptively transferred carboxyfluoroscein succinimidyl ester (CFSE)-labeled CD4 + CD25 + OT-II T reg cells in vivo (Fig. 5e) . Taken together, these results demonstrate the unique contrary effects of siA20-DCs on inhibiting T reg cell functions and hyperactivating CTLs and T helper cells.
Enhanced resistance of TILs to T reg cells during the effector phase
We also examined the effects of siA20-DCs and siS1-DCs on the effector phase of antitumor immune responses. C57BL/6 mice were inoculated with B16-OVA tumor cells and immunized 7 d later with OVA-pulsed transduced DCs, followed by in vivo polyI:C stimulation. Tumor infiltration of activated IFN-g + CD8 + and IFN-g + CD4 + T cells was enhanced in siA20-DC-treated mice, as indicated by cytokine intracellular staining (data not shown). However, there was no apparent increase in the frequency of Foxp3 + T cells in the tumorinfiltrating lymphocytes (TILs) of siA20-DC-treated mice (data not shown). ELISPOT assays further showed higher frequencies of IFN-gproducing CD8 + and CD4 + T cells in the TIL population isolated from siA20-DC-treated mice than in that from siS1-DC-treated mice (Fig. 6a) . It was also observed that the frequencies of the CD8 + and CD4 + T cells that produced both IL-6 and TNF-a in the TILs of siA20-DC-treated mice were higher than those in the TILs of siS1-DCtreated mice (Fig. 6b) . qRT-PCR assays confirmed the increased expression of IL-6 and TNF-a in the TILs of siA20-DC-treated mice, compared to that in the TILs from siS1-DC-treated mice (Fig. 6c) .
We next examined the antigen-specific proliferative activity of these TILs in immune suppressive environments. Both CD8 + CTLs and CD4 + CD25 -T helper cells isolated from the TILs of siA20-DCtreated, B16-OVA tumor-bearing mice proliferated more actively in response to OT-I peptide-or OT-II peptide-pulsed, irradiated syngeneic splenocytes than did effector T cells isolated from siS1-DC-treated, B16-OVA tumor-bearing mice, even in the presence of CD4 + CD25 + T reg cells isolated from naive mice (Fig. 6d) . In these assay conditions, OT-I peptide-or OT-II peptide-pulsed, irradiated syngeneic antigen-presenting cells (APCs) very poorly stimulated the proliferation of CD4 + CD25 + T reg cells isolated from naive mice (Fig. 6d) . These results suggest that siA20-DC-activated effector T cells are more resistant to T reg cell-mediated suppression. We also tested the suppressive activity of tumor-infiltrating T reg cells isolated from the TILs of different groups of mice. Fig. 6e shows that CD4 + CD25 + T reg cells isolated from TILs of siA20-DC-treated mice showed a lower suppressive activity than those from TILs of siS1-DCtreated mice or siGFP-DC-treated mice (Fig. 6e) . Collectively, these data, together with some of our other data (Fig. 5a-e) , suggest that siA20-DCs hyperactivate effector CD4 + T helper cells and CD8 + CTLs, leading to their enhanced tumor infiltration and resistance to T reg cellmediated suppression, in part owing to the enhanced production of proinflammatory cytokines such as IL-6 and TNF-a by these hyperactivated effector T cells inside the tumors during the effector phase.
DISCUSSION
The results of this study reveal that A20 negatively regulates the maturation, inflammatory cytokine production and immunostimulatory potency of DCs, functioning as an antigen presentation attenuator. This study further demonstrates the crucial role of A20 in DCs in controlling the magnitude of CD8 + and CD4 + T cell responses during both the priming and effector phases of the immune response. Hence, this study provides new insights into the regulation of antigen presentation and adaptive immune responses. This study provides a strategy for overcoming T reg cell-mediated suppression of antitumor immunity in an antigen-specific manner via the hyperactivation of DCs by inhibiting A20. We have shown that hyperactivated, A20-silenced DCs are almost as effective as the combination of wild-type DCs and CD25-specific antibody-mediated depletion in controlling the growth of pre-established tumors. Further studies reveal that A20 silencing has divergent effects on DCs, endowing them with the unique ability to inhibit T reg cells and hyperactivate CTL and T helper cells. The superior and unique immunostimulatory effect of siA20-DCs may be due to the broad roles of A20 in negative regulation of many proinflammatory signal transduction pathways [20] [21] [22] [23] [24] , as manifested by the spontaneous and higher surface expression of costimulatory molecules such as CD40, GITR-L and OX40L, which were found to inhibit T reg cells' suppressive activity 16, 38, 43, 44 , and the spontaneous and stronger production of proinflammatory cytokines such as IL-6 and TNF-a by A20-silenced DCs.
This study reveals the profound effect of A20-silenced DCs on the effector phase of antitumor responses. Tumor infiltration of antigenspecific, hyperactivated CTLs and T helper cells was substantially increased upon siA20-DC immunization. These tumor-infiltrating CTLs and T helper cells in siA20-DC-immunized mice were more refractory to T reg cell-mediated suppression, which may be a result of the increased production of IL-6 and TNF-a by these TILs. Moreover, tumor-infiltrating T reg cells from siA20-DC-treated mice had a reduced suppressive activity, suggesting an altered cytokine milieu inside the tumors. In support of our findings, another group has recently reported that functional T reg cells that accumulated in the inflammation tissues did not inhibit pathogenic effector T cells that secreted IL-6 and TNF-a, indicating that the inflammatory cytokine milieu may determine whether or not autoimmune inflammation can be controlled by T reg cells 45 . Several groups have also reported that overactivating CTLs can override T reg cell-mediated suppression 15, 16, 38 . Taken together, our results suggest that the inhibitory effects of hyperactivated siA20-DCs and tumor-infiltrating effector T cells on T reg cells may tip the balance from immune suppression to antitumor immunity as a collective outcome of the cells' effects on interactive networks of pro-and anti-inflammatory factors and cells in tumor-bearing mice. This study also supports the notion that antigenpresenting DCs deficient in a crucial and essential negative regulator of inflammatory signaling can hyperactivate an antitumor immune response to supersede T reg cell-mediated immune suppression.
METHODS
Mice. We purchased C57BL/6, BALB/c, H-2K b /OT-I-TCR (OT-I), and H-2K b / OT-II-TCR (OT-II) transgenic mice from Jackson Laboratories and maintained them in a pathogen-free mouse facility at BSC and USC according to institutional guidelines. This study was approved by the Institutional Animal Care and Use Committees of BCM and USC.
Peptides, proteins and cell lines. H2-K b -restricted TRP2 (SVYDFFVWL) 26 , H2-K b -restricted OT-I (SIINFEKL), H2-K b -restricted OT-II (ISQAVHAA HAEINEAGR) 32 and H2-K d -restricted mouse survivin (GWEPDDNPI and AFLTVKKQM) 27 peptides were synthesized and purified by HPLC to 495% purity by Genemed Synthesis. We dissolved all peptides in DMSO before final dilution in endotoxin-free PBS (Sigma). OVA protein was from Sigma. We obtained the mouse B cell lymphoma A20 (H2-K d ), EG.7 thymoma (H2-K b ), and CD25-specific antibody hybridoma (PC61) cell lines from American Type Culture Collection. The B16-OVA melanoma cell line (H2-K b ) was kindly provided by R. Dutton at the Trudeau Institute.
Lentiviral vector construction, production and transduction. The HIV selfinactivating vector used in this study was pTRIP-H1-BY-W modified from pTRIPDU3 CMV eGFP (ref. 32). We inserted the mouse A20 siRNA sequence into pTRIP-H1-BY-W to generate pTRIP-siA20-BY-W (LV-A20-siRNA) that contains the shRNA targeting mouse A20 (5¢-CAAAGCACUUAUUGACAGA-3¢). We generated recombinant pseudotyped lentiviral vectors by cotransfection of three plasmids into 293 cells and concentrated them by ultracentrifugation, as described previously 46 . We generated the control LV-siGFP previously 32 . We prepared and transduced mouse DCs as described in our previous study 32 .
Isolation of tumor-infiltrating lymphocytes, cytokine ELISA and flow cytometric analysis. TIL isolation is described in the Supplementary Methods online. We measured the levels of various cytokines using the supernatants of cell cultures at the indicated time points by ELISA analysis (BD Biosciences) according to the manufacturer's instructions. We stained cells with antibody conjugates and analyzed them on a FACSAria (Becton Dickinson) flow cytometer and FloJo software, as described previously 31, 32 . The antibodies used are listed in the Supplementary Methods.
T cell proliferation and suppression assays. We harvested spleens from mice, pooled them and disrupted them to obtain a single cell suspension. We purified T cells from wild-type, OT-I-transgenic or OT-II-transgenic mice by using the MACS CD8 + , CD4 + CD25 -or CD4 + CD25 + T cell isolation kits (Miltenyi Biotec). For antigenic stimulation using TCR transgenic OT-I or OT-II cells and antigen-pulsed DCs, we placed a total of 5 Â 10 4 purified T cells and 5 Â 10 3 DCs pulsed with OVA MHC class I or II peptides in each well of a round-bottom 96-well microtiter plate in triplicate in 200 ml RPMI 1640 medium supplemented with 10% FCS. For stimulation of T reg cell proliferation, we cocultured CD4 + CD25 + T reg cells (5 Â 10 4 per well) that had been isolated from the spleens of mice with DCs (5 Â 10 3 per well) in the presence of antibody to CD3 (2.5 mg/ml) for 72 h 35 For in vivo proliferation, we labeled purified CD4 + CD25 + OT-II T reg cells with 5 mM CFSE and injected 1 Â 10 7 T cells intravenously into naive mice. One day later, we injected 1 Â 10 6 OVA-pulsed or unpulsed LPS-matured DCs into the footpads. Three days after DC administration, we assessed pooled cells from the draining lymph nodes by flow cytometry (gated on CD25 + CD4 + T cells).
DC immunization and tumor models. We transduced DCs with lentivirus at a multiplicity of infection of 5-10. We then pulsed the DCs with peptides for 16 h, and after an additional 12-24 h of culture with LPS, we washed them in PBS and then injected them into mice in the rear footpad. In the therapeutic model, we injected B16-OVA or A20 tumor cells subcutaneously into the right flank of syngeneic mice. We then randomly divided the mice into groups and injected them with DCs transduced with different lentiviral vectors. In some mice, we administered polyI:C (50 mg; Invivogen) i.p. at the days indicated (Figs. 2-6 ). We measured tumor volumes two or three times per week with an electronic caliper.
Statistical analyses. For statistical analysis, we used Student's t-test with and a 95% confidence limit, defined as P o 0.05. Results are typically presented as means ± s.e.m.
Note: Supplementary information is available on the Nature Medicine website.
